How Can Botox Be The Safest Treatment in Aesthetic Medicine - And Yet Paradoxically the Most Dangerous ?
Botulinum Toxin - The Safest Treatment in Aesthetic Medicine, and the Most Dangerous A - Tale of Two Realities.
Approximately 8 million cosmetic botulinum toxin procedures are performed worldwide every year. The excellent safety record of this licensed treatment is extraordinary. The story of unlicensed use is the complete opposite. Understanding why the two are so different is one of the most important conversations in aesthetic medicine.
The numbers that define the landscape
Botulinum toxin is the most commonly performed non-surgical aesthetic procedure in the world, by a considerable margin.
According to the ISAPS 2024 Global Survey, 7.8 million botulinum toxin procedures were performed by plastic surgeons globally in 2024 alone, with the American Society of Plastic Surgeons reporting 7.4 million procedures in the United States alone. These figures cover only procedures performed by plastic surgeons; the true global volume, encompassing dermatologists, aesthetic physicians, and other qualified medical practitioners, is substantially higher.
Working conservatively from published growth data, the number of botulinum toxin injections rose by 459% from 2000 to 2020, with FDA cosmetic approval arriving in 2002. Cumulative cosmetic botulinum toxin treatments worldwide since approval sit conservatively in the region of 150 to 200 million procedures, and may be considerably more.
It is, by any measure, one of the most administered medical interventions in human history.
Against that background, the safety record of licensed cosmetic use is extraordinary. And the safety record of unlicensed use is the opposite.
The licensed safety record — what the data actually shows
The most comprehensive early analysis of botulinum toxin adverse events in cosmetic use examined all FDA adverse event reports over the 13.5 years following licensure — from December 1989 to May 2003.
Among cosmetic users, no deaths were reported. Of the 36 serious adverse events identified across the entire review period, 30 were complications already included as possible outcomes in the FDA-approved label. The remaining six serious adverse events did not display a pattern suggesting a common causal relationship to botulinum toxin.
To contextualise that figure: in 2002 alone there were approximately 1.1 to 1.6 million cosmetic botulinum toxin users in the United States. Across 13.5 years of FDA reporting, 36 serious adverse events in cosmetic use — 30 of which were already known and disclosed complications — represents a serious adverse event rate that most medical interventions would find difficult to match.
Death after botulinum toxin administration for cosmetic indications has never been documented with standard approved formulations. This is not a qualified statement. It is an absolute one, and it has held across more than three decades of widespread global use.
What those 30 recognised complications actually were
Understanding what the 30 "recognised complications" represent is important because the phrase might imply a catalogue of serious harms, when in fact it reflects something considerably more reassuring.
The FDA-approved label for Botox Cosmetic lists the known possible complications established during clinical trials before the product was approved. These include local effects, principally ptosis and brow ptosis, in which the toxin diffuses slightly beyond the intended injection site and temporarily weakens adjacent muscles. Both are distressing for the patient and preventable with correct technique, but both are temporary and always resolve as the product wears off.
The FDA label acknowledges that the effects of Botox Cosmetic may spread from the area of injection to produce symptoms consistent with botulinum toxin effects, including generalised muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties, reported hours to weeks after injection. In cosmetic use at standard aesthetic doses, this systemic spread is rare but it is a recognised possibility that clinical trial data identified, that practitioners are trained to recognise and manage, and that the consent process is supposed to cover. Several of the 30 serious adverse events in cosmetic use were presentations of exactly this kind.
Hypersensitivity reactions — anaphylaxis, urticaria, soft tissue oedema — are also listed as possible serious reactions. One fatal case of anaphylaxis has been reported in which lidocaine, used as a diluent, was the suspected cause rather than the botulinum toxin itself. This single death, attributed to the anaesthetic rather than the toxin, is the closest the licensed cosmetic record has come to a fatality and it was not caused by the botulinum toxin.
The therapeutic use comparison — and why it matters
The contrast with therapeutic botulinum toxin use is clinically instructive. Among therapeutic users over the same 13.5 year period, 217 serious adverse events were identified, including all 28 reported deaths. Every death associated with botulinum toxin in the FDA review occurred in medical therapeutic use rather than cosmetic use.
The explanation is straightforward. Therapeutic applications — cervical dystonia, spasticity, blepharospasm — require doses that are an order of magnitude higher than those used in aesthetic medicine.
The patients receiving them frequently have complex underlying medical and neurological conditions, impaired swallowing mechanisms, or reduced respiratory reserve that makes systemic toxin spread considerably more dangerous. The cosmetic doses used for glabellar lines, crow's feet, and forehead treatment are minute by comparison — and they are delivered into healthy tissue in otherwise well patients.
The distinction matters because it is sometimes cited, incorrectly, as evidence that botulinum toxin carries a significant death risk in aesthetic use. It does not. The therapeutic death data and the cosmetic safety data belong to entirely different clinical contexts, and conflating them misrepresents both.
The unlicensed reality — a very different story
Against the extraordinary safety record of licensed cosmetic use, the story of unlicensed botulinum toxin is a study in contrast. A CDC investigation identified 17 confirmed cases across 9 US states, with 13 hospitalisations, linked to counterfeit or mishandled botulinum toxin products — some received from unlicensed individuals, some purchased through online marketplaces, and some self-injected.
Symptoms in counterfeit cases included blurred or double vision, difficulty swallowing, difficulty breathing, and slurred speech — consistent with systemic botulism from uncontrolled doses of laboratory-grade toxin rather than the precisely formulated, dose-controlled licensed product. Sp
Licensed medical providers have safely administered FDA-approved botulinum toxin for decades. However, unsafe use, including counterfeit products, administration by unlicensed providers, or self-injection, has resulted in severe illnesses, with some patients requiring invasive mechanical ventilation in an Intensive Care setting.
The FDA subsequently issued warning letters to 18 companies illegally selling counterfeit or misbranded botulinum toxin products online. By 2025, the CDC was reporting additional cases of severe illness following self-injection of products purchased from online retailers, a trend that shows no sign of abating as long as the products remain accessible through unregulated channels.
Why the contrast exists — the science of the safety difference
The contrast between licensed and unlicensed botulinum toxin safety is not a regulatory abstraction. It has a precise scientific explanation.
Licensed botulinum toxin products e.g. Botox, Dysport, Xeomin, Bocouture and their equivalents are pharmaceutical-grade preparations in which the concentration of active neurotoxin is precisely characterised, standardised, and expressed in units that allow practitioners to deliver a known and accurately controlled dose. The potency of one unit of onabotulinumtoxinA (Botox) is defined against a standardised mouse lethality assay. The dose ranges used in aesthetic medicine have been established through clinical trials as sufficient to produce the desired local muscle relaxation with an adequate safety margin against systemic spread.
Counterfeit or laboratory-grade botulinum toxin, whether sourced from unregulated online suppliers, research chemical vendors, or fraudulent distributors, has no such standardisation. The concentration of active toxin is unknown and unverified. The formulation may be inappropriate for injection. The storage, transport, and handling conditions that maintain product stability may have been violated. And the person administering it may have no understanding of dose-response relationships, no knowledge of facial anatomy, and no capacity to recognise or manage a complication.
Botulinum toxin is, in its raw form, one of the most potent naturally occurring toxins known to science. The licensed aesthetic product is the same molecule, rendered safe by pharmaceutical precision, clinical-grade formulation, standardised dosing, and delivery by trained medical practitioners who understand both its mechanism and its risks. Remove any of those safeguards and you are not administering a precision medical treatment. You are administering an uncharacterised biological toxin.
The clinical and regulatory implications
The botulinum toxin safety data makes an argument that is almost impossible to counter on its merits: the product, in licensed hands, is safe to a degree that is genuinely remarkable and unmatched by almost every other licensed medicine.
However, the product outside of that framework is potentially highly dangerous. The difference between those two realities is not the molecule. It is everything that surrounds it, namely the pharmaceutical standards, the regulatory approval, the clinical training, the anatomical knowledge, the consent process, and the capacity to manage complications when they arise.
This is the same argument we have made throughout this blog in different registers: about the Wild West of UK aesthetics regulation, about the practitioner who cannot manage a vascular occlusion, about the difference between a medically qualified doctor and a weekend certificate holder. The botulinum toxin data provides perhaps the clearest and most compelling evidence base for that argument of anything we have examined.
Botox is exceptionally safe. The regulatory and clinical framework around it is what makes it safe. And every patient who chooses treatment outside that framework, from a non-medical injector, from an unlicensed med spa, or from a product purchased online, is making a decision whose risk profile is categorically different from the one the safety data describes.
The views expressed in Clinical Perspectives are the author's own and reflect their personal and professional experience in aesthetic medicine.
References
Coté TR et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. Journal of the American Academy of Dermatology. 2005;53(3):407–415. https://pubmed.ncbi.nlm.nih.gov/16112345/
ISAPS Global Survey 2024. International Society of Aesthetic Plastic Surgery. https://www.isaps.org/discover/about-isaps/global-statistics/
CDC Investigation: Harmful Reactions to Botulinum Toxin Injections. Centers for Disease Control and Prevention. 2024. https://cdc.gov/botulism/outbreaks/harmful-reactions-botox-injections
FDA Alert: Counterfeit Version of Botox Found in Multiple States. US Food and Drug Administration. 2024. https://www.fda.gov/drugs/drug-safety-and-availability/counterfeit-version-botox-found-multiple-states
CDC MMWR: Severe Illnesses After Self-Injection of Botulinum Toxin Purchased Online. 2025. https://www.cdc.gov/mmwr/volumes/74/wr/mm7438a1.htm
Nayyar P et al. Botulinum Toxin Deaths: What is the Fact? Journal of Maxillofacial and Oral Surgery. 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2840902/
FDA Prescribing Information: Botox Cosmetic (onabotulinumtoxinA). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103000s5316s5319s5323s5326s5331lbl.pdf